Report date: After market close, Wednesday, Aug 5, 2026 · Conference call 4:30 PM ET Fiscal period: Q1 FY2027 (quarter ended June 30, 2026) Stock: ~$830 (Aug 4 close) · roughly flat YTD, ~+17% over the trailing year New wrinkle: This is CFO Kenny Cheung's first earnings call (ex-Sysco CFO, started May 29, 2026; Britt Vitalone has moved to an advisory role overseeing the Med-Surg separation)
McKesson enters this quarter off a strong FY2026 — revenue of $403.4B (+12%) and adjusted EPS of $39.11 (+18%), which came in above its own long-range targets, with $6.2B of operating cash flow and $5.1B returned to shareholders. Momentum has been broad-based, and the company has topped Street EPS estimates in each of the last four quarters.
The tension going in: in May, management set FY2027 adjusted EPS guidance of $43.80–$44.60 (+12–14%) — a solid number but one the market initially found underwhelming, with the stock falling ~7% on the print before recovering through the summer. So the bar this quarter is less about the Q1 number itself and more about whether management sounds confident enough to raise the full-year guide (as it did after Q1 last year).
| Metric | Consensus | Year-ago (Q1 FY26) | Implied growth |
|---|---|---|---|
| Revenue | ~$104.3B | $97.8B | ~+6–7% |
| Adjusted EPS | ~$9.46–$9.59 | $8.26 | ~+15–16% |
A couple of things worth flagging on the comparison: - The year-ago Q1 (+5% adj. EPS) was an artificially soft comp — it was dragged by a higher tax rate and the absence of ~$110M of McKesson Ventures gains that had boosted the prior year. That flatters this year's growth optics. - Management guided FY27's EPS cadence to be "broadly similar to FY26 on a first-half/second-half basis." FY26 Q1 was ~21% of the full year; applied to the FY27 midpoint (~$44.20), that implies roughly $9.2–$9.4 — so consensus of ~$9.5 already bakes in a modest beat.
McKesson reorganized into four segments starting FY26: North American Pharmaceutical (now includes Canada), Oncology & Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical. Year-ago segment figures will be recast, so headline YoY segment growth may look different from last August's release (which still used the old U.S. Pharma / International structure). Here is the FY27 full-year growth framework management laid out:
| Segment | FY27 Rev growth | FY27 Adj. OP growth | Key drivers to watch |
|---|---|---|---|
| North American Pharmaceutical | +4–8% | +5.5–9.5% | Stable Rx utilization, specialty/health-system distribution; GLP-1 volumes; offset by IRA branded price declines (~3% rev headwind) and lapping Rite Aid |
| Oncology & Multispecialty | +14.5–18.5% | +13.5–17.5% | Provider adds (US Oncology Network), lapping PRISM Vision & Core Ventures acquisitions (Q1 last year); organic OP running ~13% |
| Prescription Technology Solutions | +2.5–6.5% | +11–15% | Access/affordability demand strong; 3PL (~55% of segment revenue) is lumpy quarter-to-quarter |
| Medical-Surgical | +1–6% | flat to +4% | Soft ambulatory/illness-season demand; separation costs |
Modeling items for the full year: Corporate expense $580–640M · interest expense $380–420M (rising on new debt) · noncontrolling interest $295–325M (Apollo) · tax rate 17–19% · FCF $4.5–4.9B · ~$5B buyback · diluted shares 116–118M.
1. Guidance revision. With MCK's habit of beating and a soft H1 comp, the key question is whether they raise the $43.80–$44.60 range. A reiteration (rather than a raise) after a Q1 beat could read as cautious.
2. Medical-Surgical separation progress. This is the biggest strategic catalyst. Key milestones: Apollo's $1.25B investment for ~13% (implying ~$13B enterprise value) closed in June; the business is already operationally/legally separate with carve-out financials done. Watch for updates on IPO timing, and on the up to $2.25B of additional term loans expected to be issued in the back half of this quarter — proceeds are earmarked principally for share buybacks.
3. GLP-1 trajectory. GLP-1 distribution hit $53B in FY26 (+27%), but Q4 showed the volatility — up 22% YoY yet down 4% sequentially. Management stresses GLP-1 has no meaningful operating-profit impact, so focus on volume commentary and the read-through to RxTS access/affordability demand rather than the revenue line.
4. Capital deployment & the new CFO's tone. MCK plans ~$5B of buybacks in FY27 (accelerated by separation proceeds), with total authorization of ~$7.7B as of April. Also watch for a potential 10th consecutive annual dividend increase (last year's 15% hike to $0.82 was announced in late July alongside Q1). Cheung's first call will be scrutinized for any change in capital-allocation or M&A posture.
5. Structural margin/mix headwinds. IRA-driven branded price declines and the biosimilar wave are the recurring bear points — lower drug prices compress distribution buy-margin dollars and Part B ASP economics. Management frames biosimilars as a long-term "win," positioned between generics and brands economically, but investors will want reassurance that specialty/oncology mix and operating efficiency (opex/gross profit improved ~293 bps in FY26) keep offsetting these.
Bottom line: MCK is a "show-me on the guide" quarter. The Q1 number is likely fine — the debate is whether specialty/oncology strength and buyback acceleration prompt a full-year raise, and how new CFO Kenny Cheung frames the Medical-Surgical spin, GLP-1 variability, and the IRA/biosimilar margin narrative on his debut call.
Note: Consensus figures are drawn from public estimate aggregators (Zacks/Yahoo/Barchart) and should be treated as approximate; all company financials and guidance are from McKesson's FY26 Q4 earnings release and call (May 7, 2026).